128 related articles for article (PubMed ID: 11799965)
1. Interleukin-15 as a potential costimulatory cytokine in CD154 gene therapy of chronic lymphocytic leukemia.
Anether G; Marschitz I; Tinhofer I; Greil R
Blood; 2002 Jan; 99(2):722-3. PubMed ID: 11799965
[No Abstract] [Full Text] [Related]
2. Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia.
Chu P; Deforce D; Pedersen IM; Kim Y; Kitada S; Reed JC; Kipps TJ
Proc Natl Acad Sci U S A; 2002 Mar; 99(6):3854-9. PubMed ID: 11891278
[TBL] [Abstract][Full Text] [Related]
3. Differential regulation of Th1 and Th2 functions of NKT cells by CD28 and CD40 costimulatory pathways.
Hayakawa Y; Takeda K; Yagita H; Van Kaer L; Saiki I; Okumura K
J Immunol; 2001 May; 166(10):6012-8. PubMed ID: 11342617
[TBL] [Abstract][Full Text] [Related]
4. CD40 ligand in CLL pathogenesis and therapy.
Schattner EJ
Leuk Lymphoma; 2000 May; 37(5-6):461-72. PubMed ID: 11042507
[TBL] [Abstract][Full Text] [Related]
5. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia.
Wierda WG; Cantwell MJ; Woods SJ; Rassenti LZ; Prussak CE; Kipps TJ
Blood; 2000 Nov; 96(9):2917-24. PubMed ID: 11049967
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154.
Wierda WG; Castro JE; Aguillon R; Sampath D; Jalayer A; McMannis J; Prussak CE; Keating M; Kipps TJ
Leukemia; 2010 Nov; 24(11):1893-900. PubMed ID: 20882050
[TBL] [Abstract][Full Text] [Related]
7. In vivo activation of signal transducer and activator of transcription 1 after CD154 gene therapy for chronic lymphocytic leukemia is associated with clinical and immunologic response.
Battle TE; Wierda WG; Rassenti LZ; Zahrieh D; Neuberg D; Kipps TJ; Frank DA
Clin Cancer Res; 2003 Jun; 9(6):2166-72. PubMed ID: 12796382
[TBL] [Abstract][Full Text] [Related]
8. CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53.
Dicker F; Kater AP; Prada CE; Fukuda T; Castro JE; Sun G; Wang JY; Kipps TJ
Blood; 2006 Nov; 108(10):3450-7. PubMed ID: 16741250
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of the CD95 receptor and defect CD40-mediated signal transduction in B-chronic lymphocytic leukemia cells.
Laytragoon-Lewin N; Duhony E; Bai XF; Mellstedt H
Eur J Haematol; 1998 Oct; 61(4):266-71. PubMed ID: 9820634
[TBL] [Abstract][Full Text] [Related]
10. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells.
Decker T; Schneller F; Sparwasser T; Tretter T; Lipford GB; Wagner H; Peschel C
Blood; 2000 Feb; 95(3):999-1006. PubMed ID: 10648415
[TBL] [Abstract][Full Text] [Related]
11. Clinical relevance of CD95 (Fas/Apo-1) on T cells of patients with B-cell chronic lymphocytic leukemia.
Groneberg C; Pickartz T; Binder A; Ringel F; Srock S; Sieber T; Schoeler D; Schriever F
Exp Hematol; 2003 Aug; 31(8):682-5. PubMed ID: 12901972
[TBL] [Abstract][Full Text] [Related]
12. CD154 (CD40 ligand).
Schönbeck U; Mach F; Libby P
Int J Biochem Cell Biol; 2000 Jul; 32(7):687-93. PubMed ID: 10856699
[TBL] [Abstract][Full Text] [Related]
13. CD40-CD40 ligand (CD154) engagement is required but may not be sufficient for human T helper 1 cell induction of interleukin-2- or interleukin-15-driven, contact-dependent, interleukin-1beta production by monocytes.
Ribbens C; Dayer JM; Chizzolini C
Immunology; 2000 Feb; 99(2):279-86. PubMed ID: 10692048
[TBL] [Abstract][Full Text] [Related]
14. CD154 gene therapy for human B-cell malignancies.
Messmer D; Kipps TJ
Ann N Y Acad Sci; 2005 Dec; 1062():51-60. PubMed ID: 16461788
[TBL] [Abstract][Full Text] [Related]
15. Fas/Fas ligand pathway, apoptosis, and clonal anergy involved in systemic acetylcholine receptor T cell epitope tolerance.
Deng C; Goluszko E; Christadoss P
J Immunol; 2001 Mar; 166(5):3458-67. PubMed ID: 11207304
[TBL] [Abstract][Full Text] [Related]
16. CD4+ T-cell induction of Fas-mediated apoptosis in Burkitt's lymphoma B cells.
Schattner EJ; Mascarenhas J; Bishop J; Yoo DH; Chadburn A; Crow MK; Friedman SM
Blood; 1996 Aug; 88(4):1375-82. PubMed ID: 8695856
[TBL] [Abstract][Full Text] [Related]
17. Differential requirement for the CD40-CD154 costimulatory pathway during Th cell priming by CD8 alpha+ and CD8 alpha- murine dendritic cell subsets.
Yasumi T; Katamura K; Yoshioka T; Meguro TA; Nishikomori R; Heike T; Inobe M; Kon S; Uede T; Nakahata T
J Immunol; 2004 Apr; 172(8):4826-33. PubMed ID: 15067060
[TBL] [Abstract][Full Text] [Related]
18. Resting B lymphocytes as APC for naive T lymphocytes: dependence on CD40 ligand/CD40.
Evans DE; Munks MW; Purkerson JM; Parker DC
J Immunol; 2000 Jan; 164(2):688-97. PubMed ID: 10623811
[TBL] [Abstract][Full Text] [Related]
19. CD40 ligation induces Apo-1/Fas expression on human B lymphocytes and facilitates apoptosis through the Apo-1/Fas pathway.
Schattner EJ; Elkon KB; Yoo DH; Tumang J; Krammer PH; Crow MK; Friedman SM
J Exp Med; 1995 Nov; 182(5):1557-65. PubMed ID: 7595225
[TBL] [Abstract][Full Text] [Related]
20. On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.
Greil R; Egle A; Villunger A
Leuk Lymphoma; 1998 Nov; 31(5-6):477-90. PubMed ID: 9922038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
